This inventor holds 238 USPTO granted patents and 124 published patent applications, plus 19 CIPO patents and 52 EPO patents, primarily in Gene Therapy (CPC class C12N15-86). Top assignees: University of Pennsylvania, Analog Devices,inc., Whitehead Institute for Biomedical Research. Active years: 1980-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Houston, TX (US) (1980)
- Durango, CO (US) (1986)
- Leesville, LA (US) (1994)
- Waltham, MA (US) (1995)
- Colorado Springs, CO (US) (1996)
- Anacoco, LA (US) (1999)
- Sharon, MA (US) (1994 - 2000)
- Ann Arbor, MI (US) (1993 - 2001)
- Avon Lake, OH (US) (2002)
- Foxboro, MA (US) (1996 - 2013)
- Gladwyne, PA (US) (1996 - 2014)
- North Adams, MA (US) (2004 - 2016)
- Foxborough, MA (US) (2016)
- Glen Mills, PA (US) (2012 - 2021)
- Philadelphia, PA (US) (2017 - 2024)
Company Filing History:
175 out of 2,665 
32 out of 3,710 
6 out of 318 
Years Active: 1980-2026
Areas of Expertise:
Title: James M Wilson: Pioneering Advancements in AAV Vectors for Gene Therapy
Introduction:
James M Wilson, a renowned scientist based in Philadelphia, PA, has made significant contributions to the field of gene therapy through his pioneering work with adeno-associated virus (AAV) vectors. With multiple patents to his name and a remarkable career, Wilson's research has greatly impacted the development of AAV vectors and their applications in gene therapy.
Latest Patents:
One of Wilson's notable patents is titled "Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer." This patent describes a method to modify the targeting and cellular uptake efficiency of AAV9 vectors by altering clade F cell surface receptors. By temporarily redirecting the vector to specific cell subsets or enhancing cellular uptake efficiency, this innovation holds promise in improving gene transfer therapies.
Another important patent held by Wilson is titled "Compositions useful in the treatment of ornithine transcarbamylase (OTC) deficiency." This patent introduces viral vectors containing engineered hOTC DNA and RNA sequences, which show potential in treating hyperammonemia, OTC deficiency, and related symptoms. Additionally, methods for utilizing hOTC in the treatment of liver fibrosis and cirrhosis in OTCD patients are also included, highlighting the versatility of this invention.
Career Highlights:
Throughout his career, James M Wilson has played a pivotal role in the development and advancement of AAV vectors for gene therapy. His groundbreaking work has paved the way for numerous gene therapy breakthroughs, raising hopes for the treatment of various genetic disorders.
Wilson's career spans prestigious institutions, including the University of Pennsylvania, where he has made significant contributions to the scientific community. His expertise and research have led to the publication of numerous scientific papers, further establishing his reputation as a leading figure in the field.
Collaborations:
James M Wilson has collaborated with several esteemed scientists during his career. Notably, he has worked closely with Guangping Gao and Mauricio R Alvira, both influential researchers in the field of gene therapy. These collaborations have facilitated the exchange of ideas, furthering the progress of AAV vector research and contributing to a greater understanding of gene therapy applications.
Conclusion:
James M Wilson's remarkable career in the field of gene therapy, particularly his pioneering contributions to AAV vectors, truly sets him apart as a leading figure in the scientific community. His numerous patents and collaborations highlight his commitment to advancing the field and improving the efficacy of gene therapies. The innovative advancements made by Wilson continue to pave the way for future breakthroughs in the treatment of genetic disorders, offering hope to patients and researchers alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile